Modern management of acute heart failure syndromes
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 7 (suppl_B) , B3-B7
- https://doi.org/10.1093/eurheartj/sui006
Abstract
Heart failure is an important and growing public health problem throughout the developed world. Clinical interest has recently focused on acute heart failure syndromes (AHFS), which make a major contribution to the substantial financial and humanistic burden of disease. Despite the undoubted clinical importance of AHFS, no universally accepted definition of the condition exists and the first treatment guidelines remain to be published. The prognosis for patients with AHFS remains poor. Many acute therapeutic interventions are yet to be validated in randomized controlled trials, although recent years have seen a number of large-scale studies and the introduction of several new treatment options. In contrast to AHFS, substantial progress has been made in developing management strategies for chronic heart failure, although use of well-established life-saving therapies remains suboptimal. A brief introduction to the current key issues in AHFS, which are discussed in more detail in this supplement, is provided in this paper.Keywords
This publication has 36 references indexed in Scilit:
- Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart FailureCirculation, 2003
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003
- RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edemaJournal of the American College of Cardiology, 2003
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Precipitating factors and decision-making processes of short-term worsening heart failure despite “optimal” treatment (from the IN-CHF Registry)The American Journal of Cardiology, 2001
- More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failureEuropean Journal of Heart Failure, 2001
- Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart FailureNew England Journal of Medicine, 2000
- Heart failure: we need more trials in typical patientsPublished by Oxford University Press (OUP) ,2000
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999
- Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL studyJournal of the American College of Cardiology, 1999